Search

In patients with coronary heart disease undergoing primary prevention, hypertriglyceridemia is a residual risk for cardiovascular events. Omega‐3 carboxylic acid (OM3‐CA), a mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may be beneficial in reducing triglyceride levels. As part of the clinical development program of OM3‐CA in China, this phase I study evaluated the pharmacokinetics, safety, and tolerability profile of OM3‐CA in healthy subjects. The pharmacokinetic results of this study were also compared with those of available data for Western populations. Fourteen healthy Chinese subjects (aged 18‐45 years) received once‐daily oral OM3‐CA 4 g for 14 consecutive days. Pharmacokinetic parameters were assessed from both baseline‐uncorrected and baseline‐corrected plasma concentrations vs time profile of EPA, DHA, and EPA plus DHA. Following single and multiple oral doses of OM3‐CA, the absorption of EPA, DHA, and EPA plus DHA was steady with median tmax occurring at 5.5–6 hours after both single and multiple dosing. Close to steady‐state concentrations in plasma were reached after 14 days of continuous once‐daily dosing, and accumulation was confirmed for EPA, DHA, and EPA plus DHA. Of the 14 subjects treated with OM3‐CA, 6 (42.9%) reported at least 1 adverse event (diarrhea) during the study, which was determined as mild and treatment emergent. No serious adverse events were reported. In summary, the pharmacokinetic profile of oral OM3‐CA 4 g after single and multiple dosing in healthy Chinese subjects is consistent with that observed in other ethnic populations. [ABSTRACT FROM AUTHOR]